- July 12, 2018 Spero Therapeutics Announces Pricing of Securities Offering
- July 09, 2018 Spero Therapeutics Announces Proposed Offering of Common Stock
- July 09, 2018 Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
- June 05, 2018 Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018
- June 01, 2018 Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June
- May 23, 2018 Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
- May 10, 2018 Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update
- May 01, 2018 Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
- April 16, 2018 Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
- April 12, 2018 Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
Displaying 11 - 20 of 68 results